Q-omics provides the consensus-scored ME3 profile across patient tissues and cancer cell-line models. ME3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ME3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ME3 protein abundance shows 29,438 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where ME3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ME3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ME3 survival associations across molecular data types. ME3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ME3 RNA expression–survival associations across cancer types. High ME3 expression shows unfavorable associations in MESO and LIHC, but favorable associations in BLCA, UCS, UVM and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ME3 RNA expression.
This table summarizes ME3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ME3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ME3 shows lower tumor expression in HNSC, UCEC and BRCA and higher tumor expression in THCA, LIHC and KICH. The THCA box plot shows higher ME3 RNA expression in tumor versus normal tissue (log2 FC = +0.970, t-test p < 0.001).
This table shows molecular features associated with ME3 in patient tissues and cancer cell lines. In patient samples, ME3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ME3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
